Better than hyaluronic acid, the collagen leader has risen more than 10 times in three years, and the full list of concept stocks has come!

Source: Data Treasure

Another variety of medical beauty track is out of the loop!

Due to the collagen theme, Jinbo Bio, a stock of the North Exchange, has a strong trend recently. On November 13th, the intraday share price of the stock once reached 298.2 yuan/share, a record high, and the market value of A shares once exceeded 20 billion yuan. At the close, the stock fell to 287.99 yuan/share.

According to the data, Jinbo Bio landed on the Beijing Stock Exchange on July 20 this year, and its main business is the research, development, production and sales of various terminal medical device products and functional skin care products with recombinant humanized collagen as the core.

After rotating the board to the North Stock Exchange, the share price of Jinbo Bio accelerated. According to the statistics of Securities Times and DataBao, in the past three years, the biggest increase in the stock range has reached more than 16 times. Because it is a stock of the North Exchange, there are still not many investors participating in the transaction. Since November, the average daily turnover of the stock is 102 million yuan, and the average daily turnover rate is less than 1%.

Collagen will becomeThe first raw material of functional skin care products

Among the ingredients of medical beauty and skin care products, there are three kinds of collagen, hyaluronic acid and plant active ingredients in the market. In contrast, collagen has more biological characteristics in providing structural support, promoting hemostasis and cell adhesion, stimulating cell regeneration and proliferation, repairing damaged skin barrier and supplementing nutrition for aging and problem skin. Its molecular weight is larger than hyaluronic acid, and its skin repair and anti-aging effects are stronger.

In recent years, with the concept of "efficacy skin care" deeply rooted in people’s hearts, many beauty lovers have focused on raw materials, among which the multiple effects of recombinant collagen have been captured by consumers. According to Frost&Sullivan’s statistics, the market of functional skin care products in China is expected to reach 211.8 billion yuan in 2025. In 2025, the market share of collagen will surpass hyaluronic acid for the first time and become the largest raw material component.

According to Jost Sullivan’s data, the market size of collagen products in China will reach 28.8 billion yuan in 2021, with a compound growth rate of 31% from 2017 to 2021. It is estimated that the market of collagen products in China will be 173.8 billion yuan in 2027, about 18 times the market size in 2017, with a compound growth rate of 35% from 2021 to 2027.

According to Jost Sullivan’s statistics, the market penetration rate of recombinant collagen is only 15.9% in 2017, 37.7% in 2021, and it is estimated that the market penetration rate will be 62.3% in 2027, and the market scale will reach 108.3 billion yuan, 10 times that of 2021.

The strong demand of collagen market has promoted the sustained and high growth of leading companies, and Jinbo Bio is one of the representatives. The data shows that since 2021, the growth rate of Jinbo Bio-profit has greatly increased, and the net profit in that year was 57 million yuan, a year-on-year increase of 79.62%; By 2022, the company’s net profit exceeded 100 million yuan for the first time, a year-on-year increase of 90.24%; In the first three quarters of 2023, the company achieved a net profit of 192 million yuan, a year-on-year increase of 173.75%, a record high.

According to Shanxi Economic Daily, from 2021 to 2023, two products, Weimei, a freeze-dried recombinant collagen III fiber for injection and humanized recombinant collagen III solution for injection, were approved for three types of medical devices, which is the first time in China. Up to now, Jinbo Bio-industrial Park has achieved an annual output of more than 3 million pieces of injection-grade humanized collagen A and 50 million pieces of sterile intelligent collagen with a single component of humanized collagen A, making up for the market demand gap of recombinant humanized collagen.

These A-share companies disclose the layout.

Since 2022, the attention of recombinant collagen market has been increasing, attracting many listed companies to enter. Recently, a number of A-share companies have responded to the layout of collagen.

Marubi shares said that recombinant collagen has been widely used in Marubi products, such as essence, cleansing, lotion, emulsion, eye cream, cream, mask and other categories.

Mingjitang Cosmetics, a subsidiary of Huaren Pharmaceutical, focuses on medical scientific skin care. At present, its main products include collagen sleep mask, small molecular collagen water, vitamin E moisturizing cream, aurora good night essence, vitamin E milk and sunscreen milk.

Huaxi Bio completed the marketing of recombinant type III human collagen raw material product (medical device grade) in August 2023, which has the functions of repairing, promoting wound healing and promoting collagen regeneration.

There are some recombinant collagen skin care products in modern Chinese medicine, such as yeast recombinant collagen dressing, yeast recombinant collagen liquid dressing, yeast recombinant collagen gel, etc., all of which belong to Class II medical devices.

Collagen products such as "yeast recombinant collagen liquid dressing" and "yeast recombinant collagen gel" produced by Betani are mainly used in the field of beauty and skin care.

Concept stocks with high growth potential are released.

In terms of secondary market performance, since November, the average daily turnover of collagen concept stocks was 174 million yuan, an increase of 28.89% from last month. The average daily turnover of Jiangsu Wuzhong, Fuerjia, Jieya, Marubi and Dongbao Bio increased by over 50% month-on-month. The volume of transactions in Wuzhong, Jiangsu Province is the most obvious, with an average daily turnover of 925 million yuan since November, an increase of 207.55% from the previous month. The stock hit an intraday high on November 1, and the latest closing price retreated 14.6% from the annual high.

From the perspective of future growth potential, there are five concept stocks whose net profit growth rate is expected to exceed 20% in the next three years, namely Freda, Jinbo Bio, Jiangsu Wuzhong, Marubi Co., Ltd. and Betani.

The average growth rate of net profit is the highest in Wuzhong, Jiangsu Province. Jiangsu Wuzhong relies on the genes of pharmaceutical companies to quickly cut into the medical beauty track, focusing on the upstream products of non-surgical medical beauty. According to the research report of CITIC Jiantou Securities, in the future, the basic plate of Jiangsu Wuzhong pharmaceutical sector is growing steadily, and the pipelines of Tongyanzhen-hyaluronic acid-recombinant collagen in the medical and beauty sector are accelerating the layout, which is expected to contribute to the performance increment.

Disclaimer: All information in DataBao does not constitute investment advice, and the stock market is risky, so investment should be cautious.